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Abstract
Recently, the Food and Drug Administration placed a “black box” label on etanercept, and other tumor necrosis
factor inhibitors used to treat childhood arthritis, warning of the risk of malignancies. The Food and Drug Adminis-
tration made their decision based on a review of 48 cases of malignancies identified worldwide in children treated
with tumor necrosis factor inhibitors for inflammatory bowel disease, sarcoidosis, and juvenile idiopathic arthritis.
Recently, an article in Pediatric Rheumatology demonstrated that there may not be an increased risk of cancer in
children with juvenile idiopathic arthritis treated specifically with the tumor necrosis factor receptor fusion protein,
etanercept. There are many confounding issues regarding whether or not etanercept increases the risk of malig-
nancy, specifically lymphomas, above the background rate of cancer in children with juvenile idiopathic arthritis
who are not being treated with biologic agents. Whether or not it was appropriate for the Food and Drug Admin-
istration to lump cancer patients with underlying granulomatous diseases (inflammatory bowel disease and sarcoi-
dosis) with children with juvenile idiopathic arthritis is explored herein. Moreover, the amalgamation of etanercept
with anti-tumor necrosis factor monoclonal antibodies (adalimumab and infliximab) is another point of contention.
What is clear is that there is much that is currently unknown to be able to convincingly demonstrate a substantial
risk of cancer in children with juvenile idiopathic arthritis treated with etanercept. Conversely, there is ample evi-
dence demonstrating remarkable benefit of etanercept in treating juvenile idiopathic arthritis. Physicians treating
childhood arthritis should weigh these potential risks and benefits with patients and their families discussing the
current limitations in available data regarding the risk of cancer in children treated with etanercept for juvenile
idiopathic arthritis.
Introduction
The bench to bedside transition of tumor necrosis factor
(TNF) inhibitors has been a truly remarkable break-
through in the treatment of both adult and pediatric
chronic inflammatory arthritis, and no less worthy than
awarding the 2003 Lasker Clinical Medical Research
Award to Drs. Feldman and Maini [1]. The first of these
wonder drugs to be approved by the Food and Drug
Administration (FDA) and used extensively to treat
juvenile idiopathic arthritis (JIA) was the TNF recep-
tor2-imumoglobulin Fc tail fusion protein, etanercept
[2]. In clinical trials, etanercept has been shown to be
safe and highly efficacious in treating JIA [3]. However,
in November 2009, the FDA placed a new black box
warning on TNF inhibitors, including etanercept, warn-
ing of the risks of malignancy. This was the result of the
FDA identifying 48 cases of malignancy occurring in
children associated with theu s eo ft h eT N Fi n h i b i t o r s ,
infliximab (31 cases), adalimumab (2 cases), and etaner-
cept (15 cases) [4]. The authors of this report estimated
that the rate of overall malignancy associated with eta-
nercept was approximately equal to the background rate
in the general population, but the rate of lymphoma was
approximately 5 times the background rate. Recently,
employees of Amgen (makers of etanercept) and collea-
gues reported in this journal that there does not appear
to be an overall increased risk of malignancy associated
with etanercept but there may be an increased risk for
lymphoma [5]. * Correspondence: rcron@peds.uab.edu
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McCroskery and colleagues identified 18 malignancies
worldwide among children who received etanercept, and
3 of these remain unconfirmed [5]. The potential risk
window for a possible causal link between etanercept
and cancer is unknown, but 5 cases had only received
etanercept for 6 months or less prior to their cancer
diagnoses. An even bigger question remains as to what
proportion of the risk of cancer in patients with JIA is
attributable to treatment with etanercept. Prior or con-
current treatment with certain non-biologic medications,
such as methotrexate (which was received by 13 of the
cases), may carry their own risks of lymphoma develop-
ment in children [6] and adults [7] with chronic inflam-
matory arthritis.
Very recent independent preliminary studies have
suggested that biologic naïve JIA patients experience
an approximately 2- to 3-fold increased risk of cancer
[8,9], and a nearly 4-fold increased risk of lymphoproli-
ferative cancers [9]. This is similar to adults with rheu-
matoid arthritis where the disease itself confers a risk
of lymphoma development [10]. Some recent large
population studies have shown no additional risk of
lymphoma conferred by TNF inhibitors in RA patients
[11,12]. Thus, it is critical to know the background
rate of malignancy in children with JIA; without this
data, there is no way of deciphering either a protective
effect or increased risk of lymphoma development in
children with JIA treated with TNF inhibitors, such as
etanercept.
What does seem likely, however, is a risk of develop-
ing hepatosplenic T cell lymphomas in children with
inflammatory bowel disease (IBD) treated with a com-
bination of azathioprine or 6-mercaptopurine (6-MP),
and a monoclonal antibody (mAb) directed against
TNF (e.g., infliximab or adalimumab) [13]. Although
some children with IBD develop arthritis and are man-
aged or co-managed by pediatric rheumatologists, it is
more likely that pediatric rheumatologists will use
methotrexate in combination with an anti-TNF mAb.
This is relevant since all the lymphoma cases identified
by the FDA in children with IBD on an anti-TNF mAb
were also treated with the thiopurines, 6-MP or
azathioprine [14]. Unfortunately, these particular lym-
phomas are often resistant to chemotherapy and are,
therefore, frequently fatal [15]. Since granulomatous
diseases (e.g., IBD, sarcoidosis) tend to respond better
to anti-TNF mAb therapy [16], etanercept is rarely
used to treat IBD. It remains unclear whether or not
etanercept also contributes to increased risk of lym-
phomas in autoimmune disorders. Nevertheless, most
all JIA patients treated with etanercept survived their
various malignancies [4].
Conclusions
It is often difficult for the FDA to choose when to alert
the public about a potential drug-related safety issue as
they rarely have adequate information to make definitive
conclusions at the time of the warning. However, it
remains questionable whether or not the FDA should
have lumped different classes of TNF inhibitors and dif-
ferent patient populations with differing malignancies
together and placed a generic black box warning on the
TNF inhibitors for malignancy risk, particularly in the
setting of JIA patients treated with etanercept. For rare
diseases and rare events, it is extremely difficult to
determine causality. Accordingly, interested parties have
called for the creation of a consolidated registry to
monitor the long-term safety of pediatric rheumatology
treatments [17]. Until then, physicians and JIA patient
families need to be aware of the current evidence, as
well as the large gaps in data, to make intelligent
informed decisions regarding weighing the clear benefits
afforded by TNF inhibitors versus the potential risks of
malignancy in children with JIA receiving etanercept
therapy.
List of abbreviations
Abbreviations are defined in the text where first used.
Acknowledgements
RQC was supported in part by the Arthritis Foundation, Alabama Chapter
Endowed Chair in Pediatric Rheumatology.
Authors’ contributions
RQC researched the subject and drafted the manuscript.
TB researched the subject and modified the manuscript accordingly.
Both authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 28 July 2010 Accepted: 16 August 2010
Published: 16 August 2010
References
1. Feldmann M, Maini RN: Lasker Clinical Medical Research Award. TNF
defined as a therapeutic target for rheumatoid arthritis and other
autoimmune diseases. Nat Med 2003, 9:1245-1250.
2. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ,
Stein LD, Gedalia A, Ilowite NT, Wallace CA, Whitmore J, Finck BK:
Etanercept in children with polyarticular juvenile rheumatoid arthritis.
Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000,
342:763-769.
3. Lovell DJ, Reiff A, Ilowite NT, Wallace CA, Chon Y, Lin SL, Baumgartner SW,
Giannini EH: Safety and efficacy of up to eight years of continuous
etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis
Rheum 2008, 58:1496-1504.
4. Diak P, Siegel J, La Grenade L, Choi L, Lemery S, McMahon A: Tumor
necrosis factor alpha blockers and malignancy in children: forty-eight
cases reported to the Food and Drug Administration. Arthritis Rheum
2010, 62:2517-2524.
5. McCroskery P, Wallace CA, Lovell DJ, Stryker S, Chernyukhin N, Blosch C,
Zack DJ: Summary of worldwide pediatric malignancies reported after
exposure to etanercept. Pediatr Rheumatol Online J 2010, 8:18.
Cron and Beukelman Pediatric Rheumatology 2010, 8:23
http://www.ped-rheum.com/content/8/1/23
Page 2 of 36. Cleary AG, McDowell H, Sills JA: Polyarticular juvenile idiopathic arthritis
treated with methotrexate complicated by the development of non-
Hodgkin’s lymphoma. Arch Dis Child 2002, 86:47-49.
7. Franklin J, Lunt M, Bunn D, Symmons D, Silman A: Incidence of lymphoma
in a large primary care derived cohort of cases of inflammatory
polyarthritis. Ann Rheum Dis 2006, 65:617-622.
8. Harrison M, Nordstom B, Gu Y, Mercaldi C, Aquino P, Mines D: Risk of
malignancy in biologics-naive juvenile arthritis patients (abstract). Ann
Rheum Dis 2010, 69(Suppl3):631.
9. Simard JF, Neovius M, Hagelberg S, Askling J: Juvenile idiopathic arthritis
and risk of cancer: a nationwide cohort study (abstract). Ann Rheum Dis
2010, 69(Suppl3):81.
10. Kaiser R: Incidence of lymphoma in patients with rheumatoid arthritis: a
systematic review of the literature. Clin Lymphoma Myeloma 2008, 8:87-93.
11. Askling J, Baecklund E, Granath F, Geborek P, Fored M, Backlin C,
Bertilsson L, Coster L, Jacobsson LT, Lindblad S, Lysholm J, Rantapää-
Dahlqvist S, Saxne T, van Vollenhoven R, Klareskog L, Feltelius N: Anti-
tumour necrosis factor therapy in rheumatoid arthritis and risk of
malignant lymphomas: relative risks and time trends in the Swedish
Biologics Register. Ann Rheum Dis 2009, 68:648-653.
12. Wolfe F, Michaud K: Biologic treatment of rheumatoid arthritis and the
risk of malignancy: analyses from a large US observational study. Arthritis
Rheum 2007, 56:2886-2895.
13. Lakatos PL: Is there a benefit from the concomitant use of
immunosupression with anti-TNF in Crohn’s disease; heads or tails? Rev
Recent Clin Trials 2009, 4:152-158.
14. Ochenrider MG, Patterson DJ, Aboulafia DM: Hepatosplenic T-cell
lymphoma in a young man with Crohn’s disease: case report and
literature review. Clin Lymphoma Myeloma Leuk 10:144-148.
15. Savage KJ: Prognosis and primary therapy in peripheral T-cell
lymphomas. Hematology Am Soc Hematol Educ Program 2008:280-288.
16. Rigby WF: Drug insight: different mechanisms of action of tumor
necrosis factor antagonists-passive-aggressive behavior? Nat Clin Pract
Rheumatol 2007, 3:227-233.
17. Smith MY, Sobel RE, Wallace CA: Monitoring the long-term safety of
therapies for children with juvenile idiopathic arthritis: time for a
consolidated patient registry. Arthritis Care Res (Hoboken) 62:800-804.
doi:10.1186/1546-0096-8-23
Cite this article as: Cron and Beukelman: Guilt by association - what is
the true risk of malignancy in children treated with etanercept for JIA?.
Pediatric Rheumatology 2010 8:23.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Cron and Beukelman Pediatric Rheumatology 2010, 8:23
http://www.ped-rheum.com/content/8/1/23
Page 3 of 3